Contemporary Tailored Oncology Treatment of Biliary Tract Cancers.

Gastroenterol Res Pract · 2019 · PMC6935796 · PMID 31929787

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

BILCAP did not reach statistical significance for the primary endpoint of OS in the intention-to-treat population; however, a significant OS difference was observed in the per-protocol population (only 17 patients less than the intention-to-treat population) with a median OS of 53 months in the capecitabine arm compared to 36 months in the observation arm (HR 0.75).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.